BIIB: Tau Alzheimer’s Data And EPS Upside Will Drive Future Upside

Biogen's updated analyst price target has shifted from about $206 to $219, as analysts weigh mixed but encouraging tau program data, potential EPS upside, and a modestly higher assumed future P/E multiple.

Analyst Commentary

Recent research views on Biogen cluster around mixed tau data, potential earnings power, and how much of that is already reflected in the stock's valuation.

Bullish Takeaways

Bullish analysts see the tau program update as encouraging despite the missed primary endpoint, pointing to nuanced signals in the data that could support the Alzheimer's franchise over time.
Some expect the current EPS forecast of about US$15 to have room for upside, which supports using a modestly higher future P/E multiple in their models.
Several firms highlight the CELIA topline readout as "historic," citing replicable tau pathology reduction and directional cognitive benefit across all doses in a Phase 2 setting as an important proof of concept.
Positive readthrough from Biogen's tau work to other neurology and rare disease programs, as well as to external partners, is seen as a potential growth driver that could support higher valuation multiples.

Bearish Takeaways

Bearish analysts focus on the missed primary endpoint in the Phase 2 BIIB080 study and the absence of a clean dose response, which adds execution risk to the tau program and may limit how much credit they give the stock for Alzheimer's optionality.
Some point to the need for larger, more definitive trials before assigning higher value to the tau franchise, which tempers how aggressively they adjust price targets or P/E assumptions.
A few firms maintain more cautious ratings despite modest price target adjustments, citing broader uncertainties around macro conditions and sector risk appetite that can cap near term multiple expansion.
The mixed nature of the tau data, with benefits described as directional rather than clearly conclusive, keeps some analysts conservative on long term growth expectations embedded in their models.

What's in the News

Biogen and Denali reported that BIIB122 did not slow Parkinson’s disease progression in the Phase 2b LUMA trial, and the partners plan to discontinue development of BIIB122 in idiopathic Parkinson’s disease while Denali continues the BEACON study in LRRK2 variant carriers (Key Developments).
Biogen announced Phase 2 CELIA data for diranersen in early Alzheimer’s disease, with the study missing its primary dose response endpoint but showing reductions in tau pathology and signals of slowed cognitive decline. Biogen plans to move the drug into registrational development, with FDA Fast Track status already in place (Key Developments).
Eisai and Biogen reported that the FDA extended the PDUFA date to August 24, 2026, for the once-weekly subcutaneous initiation dose of LEQEMBI IQLIK for early Alzheimer’s disease after the agency requested additional information, while stating that it has not raised approvability concerns to date (Key Developments).
Biogen agreed to acquire TJ Bio’s Greater China rights to felzartamab for up to US$850 million in upfront and potential milestone payments plus royalties, giving Biogen worldwide rights to a Phase 3 asset in multiple immune mediated diseases and expanding its role in kidney and hematologic indications in China (Key Developments).
Alloy Therapeutics and Biogen entered a collaboration for Alloy’s AntiClastic ASO platform so Biogen can apply the technology to multiple antisense programs, with Alloy eligible for upfront, milestone and tiered royalty payments on any resulting products (Key Developments).

Valuation Changes

Fair Value: The updated analyst fair value estimate has moved from about $205.67 to about $219.27, reflecting a modest upward adjustment in the modeled intrinsic value.
Discount Rate: The discount rate assumption is essentially unchanged, moving slightly from 7.49% to 7.49%, indicating a stable view of risk in the cash flow model.
Revenue Growth: The long term revenue growth input has shifted from a prior decline of about 1.45% to projected growth of about 2.40%, signaling a more constructive stance on top line prospects.
Profit Margin: The modeled net profit margin has been trimmed from about 21.91% to about 20.28%, which assumes slightly lower profitability on future earnings.
Future P/E: The future P/E multiple has risen from about 18.10x to about 18.88x, implying a somewhat higher valuation multiple applied to expected earnings.

8 views

Key Takeaways

Biogen is positioned for long-term growth through expanding global access to key therapies, leveraging increasing disease diagnoses and improved healthcare infrastructure.
Streamlined operations, diverse late-stage pipeline, and digital engagement efforts are expected to strengthen earnings and reduce future revenue volatility.
Biogen faces intense competition, pricing, and policy pressures, making its future growth highly dependent on the success of a few new product launches.

Catalysts

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.What are the underlying business or industry changes driving this perspective?

Demand for Biogen's Alzheimer's therapy LEQEMBI is poised for structural long-term growth, supported by a rapidly aging global population and accelerating rates of mild cognitive impairment diagnoses facilitated by breakthroughs in blood-based biomarkers and expanding diagnostic infrastructure. These factors position Biogen to capture a larger patient pool and drive sustained revenue expansion.
Broad international rollout and expanding reimbursement for SKYCLARYS and ZURZUVAE, particularly in rare diseases and underpenetrated markets, leverages growing global healthcare spending and improvements in medical infrastructure worldwide, increasing access and boosting long-term topline growth.
Enhancements in operational efficiency through ongoing "Fit for Growth" initiatives, disciplined cost management, and portfolio prioritization are expected to improve cost control, drive higher net margins over time, and support stronger earnings.
Robust late-stage and diversified neurodegenerative and specialty disease pipelines-including Phase III launches in SMA, lupus, and kidney indications-capitalize on regulatory momentum to address high unmet needs, creating multiple shots on goal that reduce future revenue volatility and support long-term earnings stability.
Adoption of digital health, streamlined diagnostics, and direct-to-consumer patient engagement campaigns (especially for LEQEMBI) are expected to accelerate diagnosis, increase therapy uptake, and support value-based pricing, contributing to higher revenue and improved margin capture.

Biogen Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Biogen's revenue will grow by 2.4% annually over the next 3 years.
Analysts assume that profit margins will increase from 13.8% today to 20.3% in 3 years time.
Analysts expect earnings to reach $2.2 billion (and earnings per share of $13.77) by about May 2029, up from $1.4 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $2.6 billion in earnings, and the most bearish expecting $1.8 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 19.0x on those 2029 earnings, down from 20.9x today. This future PE is greater than the current PE for the US Biotechs industry at 16.2x.
Analysts expect the number of shares outstanding to grow by 0.7% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.49%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Ongoing and accelerating competitive pressures in the ex-U.S. multiple sclerosis (MS) business, particularly for TECFIDERA in Europe due to generic and biosimilar entrants, are expected to impact revenue and market share, leading to potential further erosion of international sales and profit margins.
Despite claims of pipeline advancement, Biogen's future growth remains heavily dependent on the commercial performance of a small number of new launches (e.g., LEQEMBI, SKYCLARYS, ZURZUVAE); any clinical, regulatory, or commercial setbacks for these assets could threaten revenue stability and long-term earnings.
Industry-wide shifts toward biosimilars and generics, as well as government and payer policy pressures around high-cost specialty therapies (including mounting reimbursement challenges and discount dynamics, especially in international markets), are likely to compress gross margins and restrain topline growth for Biogen's core branded portfolio.
The Alzheimer's and lupus markets are becoming increasingly competitive with the entry of new therapies and alternative modalities; Biogen may face headwinds related to differentiation, efficacy, and market adoption, which could dampen the ramp-up of key pipeline assets and future revenue streams.
The sustainability of cost controls and margin expansion (via Fit for Growth and restructuring initiatives) is uncertain, especially as Biogen plans increased R&D investments and faces higher interest costs from additional debt-potentially pressuring net earnings if topline growth does not keep pace.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $219.27 for Biogen based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $300.0, and the most bearish reporting a price target of just $150.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $10.7 billion, earnings will come to $2.2 billion, and it would be trading on a PE ratio of 19.0x, assuming you use a discount rate of 7.5%.
Given the current share price of $193.76, the analyst price target of $219.27 is 11.6% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Biogen?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Easing Policy Risks And New Therapy Launches Will Drive Shares Higher